A Randomized, Double-blind, Placebo-controlled, Phase Ib/II Clinical Study to Evaluate the Preliminary Efficacy, Safety, Pharmacokinetic Profiles and Immunogenicity of JS016 in Participants With Mild and Moderate COVID-19 or of SARS-CoV-2 Asymptomatic Infection
Latest Information Update: 19 Jul 2022
At a glance
- Drugs Etesevimab (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Shanghai Junshi Biosciences
Most Recent Events
- 14 Jul 2022 Status changed from recruiting to completed.
- 27 Dec 2021 Planned End Date changed from 30 Oct 2021 to 30 Mar 2022.
- 27 Dec 2021 Planned primary completion date changed from 1 Oct 2021 to 30 Mar 2022.